153 related articles for article (PubMed ID: 21175373)
1. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study.
Herschorn S; Pommerville P; Stothers L; Egerdie B; Gajewski J; Carlson K; Radomski S; Drutz H; Schulz J; Barkin J; Hirshberg E; Corcos J
Curr Med Res Opin; 2011 Feb; 27(2):375-82. PubMed ID: 21175373
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
3. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Herschorn S; Vicente C; Piwko C
J Med Econ; 2010; 13(3):508-15. PubMed ID: 20690893
[TBL] [Abstract][Full Text] [Related]
4. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
5. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.
Vardy MD; Mitcheson HD; Samuels TA; Wegenke JD; Forero-Schwanhaeuser S; Marshall TS; He W
Int J Clin Pract; 2009 Dec; 63(12):1702-14. PubMed ID: 19930331
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
7. Solifenacin significantly improves all symptoms of overactive bladder syndrome.
Chapple CR; Cardozo L; Steers WD; Govier FE
Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
9. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
[No Abstract] [Full Text] [Related]
10. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Oresković S; But I; Banović M; Goldstajn MS
Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
Mattiasson A; Masala A; Morton R; Bolodeoku J;
BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
[TBL] [Abstract][Full Text] [Related]
14. [Solifenacin in the treatment of overactive bladder: results of a randomized double-blind, placebo-controlled study].
Ibinaeva IS; Apolikhina IA; Makhmedzhanova FN; Muslimova SZ
Urologiia; 2012; (5):24-8. PubMed ID: 23342612
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
But I; Goldstajn MS; Oresković S
Coll Antropol; 2012 Dec; 36(4):1347-53. PubMed ID: 23390832
[TBL] [Abstract][Full Text] [Related]
16. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W
Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
19. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Wong C; Duggan P
J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
